Refine by
Drugs For Therapeutics Articles & Analysis: Older
72 news found
Ace Therapeutics is proud to announce the launch of its cardiovascular disease model development services, aiming to empower researchers and pharmaceutical companies with advanced tools and models to accelerate the study of cardiovascular diseases and drug discovery. ...
This versatility enables the development of advanced solutions for targeted therapies, allowing adaptation of MOFs to specific therapeutic interventions. Strengthening Drug Delivery with Advanced Expertise CD Formulation’s MOF customization service stands out due to its strong foundation in research and technological expertise. ...
Ace Therapeutics, a preclinical contract research organization (CRO) actively engaged in mental illness research, has announced the launch of its model development services, which aim to revolutionize psychiatric drug research and development. ...
To help pharmaceutical partners and academic institutions overcome the challenges of low bioavailability and unsustainable drug release in drug formations for glaucoma, Ace Therapeutics is proud to announce the unveiling of its cutting-edge drug delivery system development services for the treatment of glaucoma. ...
Stem cells have revolutionized cell-based therapeutics, drug discovery and many other scientific fields. However, despite significant advancements in iPSC culture, several challenges remain regarding the reliability, reproducibility and consistency of cell cultures, assays and data. ...
CD Formulation has been dedicated to pharmaceutical advancements, showcasing immense expertise in the development and optimization of micro-reservoir controlled-release drug delivery systems. These innovative systems have revolutionized the way medications are administered, enhancing patient comfort and ensuring optimal therapeutic efficacy. ...
With the development of genetic diagnostics for rare diseases, advances in vector delivery technologies and biotechnologies such as CRISPR-Cas9, gene therapy has become one of the key research directions for therapeutic drugs for rare ...
CD Formulation's expertise in microneedle technology enables the development of novel drug delivery systems that cater to specific therapeutic needs. Another area of expertise lies in oral thin film technology. ...
Prominent within the field of computational biology, CD ComputaBio, unveils its cutting-edge Antibody Drug Design Services and Antibody Development solutions. Driven by an unwavering commitment to advancing precision medicine, the company stands at the forefront of redefining therapeutic strategies and expediting drug discovery processes, ...
Alfa Chemistry serves as an emerging pharmaceutical research organization with a mission to revolutionize the field of preclinical drug research with its wide range of comprehensive services. With a commitment to quality and excellence, Alfa Chemistry offers pharmacological analysis, drug safety evaluation, pharmacokinetic analysis, and bioanalytical services to ...
In this, nanoRBC is a major breakthrough (after a half-century of failed efforts by many companies) in the development of a safe alternative to RBC transfusion. nanoRBC, also holds great promise for use as a therapeutic in a wide variety of conditions involving the vasculature. Due to its mechanism of action, it may also be of interest to pharmaceutical companies for improving ...
Tony is currently the CEO of Evox Therapeutics, an Oxford-based company developing exosome therapeutics, and has an extensive background in mRNA and more specifically LNPs through his roles at Moderna and Alnylam. ...
ByeTheRNA
One of the most significant post-translational modifications during protein characterization is glycosylation. It affects the drug's biological activity, serum half-life, stability, and immunogenicity, which alters how the drug interacts with the patient's cells. This is a crucial quality attribute of therapeutic protein drugs. ...
The company’s first candidate targets the prostate specific membrane antigen (PSMA) in prostate cancer, which is proposed to have both diagnostic and therapeutic applications. Two drugs are being developed, CTT1057 and CTT1403, both targeting the prostate cancer biomarker, PSMA. PSMA expression is significantly higher in prostate cancer cells, increasing ...
The compound is also being developed by Enalare for the treatment of post-operative respiratory depression and community drug overdose. Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life threatening critical care conditions and community based health emergencies, announced today that ...
iBio is jockeying for position as a leading player in Al-powered drug discovery while also expanding its immuno-oncology pipeline after closing on the acquisition of multiple assets from its partner, RubrYc Therapeutics. The plant-based drug developer and contract development and manufacturing organization (CDMO) said the deal shores up its ...
The acquired assets include: AI Drug Discovery Platform: A patented system that uses artificial intelligence (“AI”) to design 3D models of epitopes to facilitate the creation of better antibody drug candidates. ...
Next-generation Medtech innovator Kurve Therapeutics begins an equity crowdfunding journey with its $50 million Regulation A+ raise. ...
Immediate applications of Lifespin’s commercial services, which leverages access to Lifespin’s proprietary software and database, include quality control for synthetic/natural compounds, quantitative profiling of metabolites in liquid samples, monitoring of drug responses and organ-specific metabolic phenotyping, and precision nutrition to therapeutic ...
Kurve Therapeutics has developed a cutting-edge approach to treating central nervous system (CNS) disorders. ...